Aptar Digital Health Reports Positive Impact of iPUMP® on Sublingual Liquid Allergen Immunotherapy Adherence
CRYSTAL LAKE, Ill., April 14, 2025--(BUSINESS WIRE)--Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announces the positive results from the SPEED1 survey, showcasing the impact of the iPUMP® connected assistant on adherence to Stallergenes Greer's sublingual liquid immunotherapy (SLIT). The results will be presented by Stallergenes Greer, a global leader in allergy therapeutics and long-standing partner of Aptar Digital Health, at the upcoming CFA congress (Congrès Francophone d'Allergologie) in Paris, France from April 15 to 18, 2025.
The SPEED survey showed a 15% increase in treatment adherence for patients using iPUMP®. Moreover, for children aged between 5 and 12 years, parental involvement in treatment administration dropped from 50% to 28% over three months, while the proportion of children independently taking their medication rose from 24% to 58%. Notably, 90% of parents felt reassured by the connected assistant, with half of them feeling completely at ease with treatment administration, compared to 36% of respondents in the non-iPUMP® group.
iPUMP®, developed in conjunction with Stallergenes Greer, supports adherence to personalized SLIT treatments by helping to ensure patients adopt the correct dosing technique, duration and frequency of treatment. This innovative and easy-to-use tool is connected to a companion mobile application and provides direct access to the personalized treatment protocol prescribed to each patient by their physician. Launched in February 2023 in France, it has been used by over 9,000 patients to date. iPUMP® helps support patients in improving treatment adherence to optimize effectiveness while offering a history-tracking function for precise medication monitoring.
By supporting Stallergenes Greer in their mission to empower individuals and improve treatment outcomes, Aptar Digital Health fosters its go-to partner position in the pharmaceutical industry for the development and operation of digital health and connected solutions.
Elena Rizova, Chief Medical Officer at Stallergenes Greer, stated, "Findings of the SPEED survey underscore the role of connected health solutions in improving both treatment adherence and patient confidence, which are key elements in achieving successful therapeutic outcomes." She added, "Innovation is at the heart of what we do and iPUMP®, by catering to the needs expressed by patients and healthcare professionals, meets their expectations and provides a solution to enhance treatment management and overall allergy care."
Marcus Bates, VP Business Development & Global Head of Respiratory at Aptar Digital Health, commented, "The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management, enabling new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes."
The SPEED survey results establish a strong foundation for broader adoption of iPUMP®, supporting Stallergenes Greer's commitment to innovate for the benefit of patients, caregivers and the medical community.
About Aptar Digital Health
Aptar Pharma's Digital Health division is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health's offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries. For more information, visit www.aptardigitalhealth.com and www.aptar.com.
About Stallergenes Greer
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit www.stallergenesgreer.com.
1 The SPEED real-life study was conducted by AplusA for Stallergenes Greer between May 29 and November 29, 2024. This online questionnaire, aimed at measuring the impact perceived by patients after three months of treatment with allergen immunotherapy (AIT) using Aptar Digital Health's iPUMP® connected assistant, included 104 pediatric patients over 5 years of age and 77 adolescent and adult patients over 13 years of age.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250414888515/en/
Contacts
Media Contact: Ciara JacksonAptar Pharma+49 151 1951 6502ciara.jackson@aptar.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio
Yahoo
17 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
